Appendix 4C - Quarterly - 30 September 2017
Filed with ASX · · 7 pages · English
Story so far
Earlier from Patrys
- PAB and Garvan Institute of Medical Research Awarded Grant
- US Patent Granted for Preclinical Candidate PAT-LM1
- PAT-DX1 Conjugated to Nanoparticles, Targets Tumors
- PAT-DX1 Active in Pre-clinical Cancer Models
- Appendix 4E and 2017 Annual Report
Later from Patrys
- Collaboration with WEHI
- PAT-DX1 is synergistic with PARP inhibitor
- Entitlement Offer Booklet
- PAT-DX1-NP Localizes to Lymph Node Metastases
- Publication and Patent Filing for Humanized Version of 3E10
Follow Patrys into a list and get an email when it puts out news.
Follow Patrys